Synergy of Hydeal-D<sup>®</sup> and Hyaluronic Acid for Protecting and Restoring Urothelium: In Vitro Characterization

Interstitial cystitis (IC) or painful bladder syndrome is a chronic dysfunction due to an inflammatory condition, characterized by bladder pain and urinary frequency. Currently, no gold standard therapy is available since IC does not respond to conventional ones. Given these premises, the aim of thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco Ruggeri (Author), Mauro Pavan (Author), Matteo Soato (Author), Susi Panfilo (Author), Carlo Barbera (Author), Devis Galesso (Author), Dalila Miele (Author), Silvia Rossi (Author), Alba Di Lucia (Author), Franca Ferrari (Author), Giuseppina Sandri (Author)
Format: Book
Published: MDPI AG, 2021-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8156df9df75a403d9d07a8170d6e5021
042 |a dc 
100 1 0 |a Marco Ruggeri  |e author 
700 1 0 |a Mauro Pavan  |e author 
700 1 0 |a Matteo Soato  |e author 
700 1 0 |a Susi Panfilo  |e author 
700 1 0 |a Carlo Barbera  |e author 
700 1 0 |a Devis Galesso  |e author 
700 1 0 |a Dalila Miele  |e author 
700 1 0 |a Silvia Rossi  |e author 
700 1 0 |a Alba Di Lucia  |e author 
700 1 0 |a Franca Ferrari  |e author 
700 1 0 |a Giuseppina Sandri  |e author 
245 0 0 |a Synergy of Hydeal-D<sup>®</sup> and Hyaluronic Acid for Protecting and Restoring Urothelium: In Vitro Characterization 
260 |b MDPI AG,   |c 2021-09-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics13091450 
500 |a 1999-4923 
520 |a Interstitial cystitis (IC) or painful bladder syndrome is a chronic dysfunction due to an inflammatory condition, characterized by bladder pain and urinary frequency. Currently, no gold standard therapy is available since IC does not respond to conventional ones. Given these premises, the aim of this work was the in vitro characterization of biological properties (mucoadhesion and anti-inflammatory activity) of a commercial product (HydealCyst-HydC) based on hyaluronic acid (HA) and the benzyl ester of HA (Hydeal-D<sup>®</sup>) intended for bladder instillation to restore and/or protect the urothelial layer of glycosamino glycans (GAGs). The in vitro characterization demonstrated that an interaction product is formed between HA and Hydeal-D<sup>®</sup> that has a role in the rheological behavior and mucoadhesive properties. HA was identified as a key component to form the mucoadhesive joint, while the interaction of HA with Hydeal-D<sup>®</sup> improved polysaccharide stability and prolonged the activity <i>ex vivo</i>. Moreover, HydC is cytocompatible with urothelial cells (HTB-4) and possesses an anti-inflammatory effect towards these cells by decreasing the secretion of IL-6 and IL-8, which were both increased in patients with IC, and by increasing the secretion of sulfated GAGs. These two findings, along with the resilience properties of the formulation due to mucoadhesion, suggest the active role of HydC in protecting and restoring urothelium homeostasis. 
546 |a EN 
690 |a HydealCyst 
690 |a hyaluronic acid 
690 |a interstitial cystitis 
690 |a urothelial cell model 
690 |a mucoadhesion 
690 |a in vitro inflammatory model 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 13, Iss 9, p 1450 (2021) 
787 0 |n https://www.mdpi.com/1999-4923/13/9/1450 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/8156df9df75a403d9d07a8170d6e5021  |z Connect to this object online.